Translational Immunology: Vaccines and Autoimmunity
My research focuses on human immunology. Leveraging clinical cohorts and cutting-edge techniques, we study autoimmune diseases, the human immune response to vaccination and the safety of vaccines. The overarching aim of our research is improving Vaccines for Vulnerable Populations, such as older adults and immunocompromised individuals and find better ways to diagnose and treat autoimmune vasculitis.
The two key areas of our research includes:
Vaccination Research
- Repeated Vaccination: using clinical cohort studies we investigate the impact of repeated vaccinations (e.g., seasonal influenza vaccination) on immune responses. We explore how repeated exposure affects B cell diversity and vaccine efficacy, aiming to improve protection against viral variants.
- mRNA Vaccine Responses: We study how host factors modulate the immune response to mRNA COVID vaccines, to enhance vaccine efficacy.
- Human In Vitro Vaccination Models: In the lab, we use a tonsil-based organoid model to study vaccine responses, offering a preclinical platform for testing vaccine candidates and adjuvants.
- Vaccine Safety: We investigate rare adverse events, including vaccine-induced autoimmunity, and aim to improve safety monitoring through systems like SmartVax, a patient-centered feedback tool.
Large Vessel Vasculitis (GCA), an autoimmune/autoinflammatory disease of the large arteries
- Molecular Immunopathogenesis: In the lab we investigates the role of T cells in autoimmunity, particularly in giant cell arteritis (GCA). By analyzing TCR repertoires and immune responses in patients, we aim to identify potential targets for novel treatments such as antigen-specific tolerance induction.
- Clinical Biomarkers: We works on improving diagnosis and personalized treatment strategies for GCA, using biomarkers like IL-6 for monitoring disease activity and relapses. We also explore the role of imaging modalities and autoantibody profiles for better diagnostics and prognostics.